U.S. Degenerative Disc Disease Treatment Market
U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2021 - 2028)
U.S. Degenerative Disc Disease Treatment Market, by Treatment (Epidural Steroid Injections, Narcotics (Morphine, Methadone Hydrochloride, Codeine, Hydrocodone, Tramodol, Oxycodone, and Others), Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products) Phase I, Phase II, and Phase III), by Disease Indication (Early Stage, Mid Stage, and Late Stage), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
- Published In: 18 Aug, 2021
- Code: CMI4590
- Page number: 179
- Formats: Excel and PDF
- Industry: Pharmaceutical
Table of Contents (Version-2026)
Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Coherent Opportunity Map (COM)
- Report Description
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Patient Journey
- Epidemiology
- Patient Funnel
- Patient Treatment Journey and Patient Share, By Treatment Type
- Patient Share By Product Type In Overall Diagnosed Population
- DDD Patient Numbers, By Pfirrmann Grade
- Product Launch/Approvals
- Acquisition, Collaboration & Agreements
- Key Developments
- Therapeutic Landscape
- Future Therapeutic Landscape
- Market Dynamics
U.S. Degenerative Disc Disease Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
- Impact of Covid-19 on Supply and Demand of Degenerative Disc Disease Drugs
- Impact on R&D activities of Degenerative Disc Disease therapeutics
U.S. Degenerative Disc Disease Treatment Market, By Treatment Type, 2017 – 2028, Million (Number of Patient)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018– 2028
- Segment Trends
- Epidural Steroid Injections
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Narcotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Morphine
- Methadone Hydrochloride
- Codeine
- Hydrocodone
- Tramodol
- Oxycodone
- Others
- Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Phase I
- Phase II
- Phase III
- Introduction
U.S. Degenerative Disc Disease Treatment Market, By Disease Indication, 2017 – 2028, Million (Number of Patient)
- Overview
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Early Stage
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Mid Stage
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Late Stage
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Overview
U.S. Degenerative Disc Disease Treatment Market, By Distribution Channel, 2017 – 2028, Million (Number of Patient)
- Overview
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, Million (Number of Patient)
- Overview
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- AnGes Inc.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Ankasa Regenerative Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- BIOPHARM GMBH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- BioRestorative Therapies Inc.
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Biosplice Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Bone Therapeutics SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Cerapedics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- DON
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Creative Medical Technology Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- DiscGenics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Ferring Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- FibroGenesis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Geistlich Pharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Harbor View Medical Services, PC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Intralink-Spine, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Isto Biologics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Kolon TissueGene Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Kunovus
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Lineage Cell Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Mesoblast
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- NC Biomatrix BV
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Notogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- R3 Stem Cell
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Smith & Nephew
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Spine BioPharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Stayble Therapeutics AB
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- US Stem Cell Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- VIVEX Biologics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- AnGes Inc.*
- Analyst Views
Section
- Research Methodology
- About us
*Browse 6 market data tables and 16 figures on "U.S. Degenerative Disc Disease Treatment Market ” - forecast to 2028
-
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
EXISTING CLIENTELE
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
